As sPD-L1 retains the ability to bind PD-1 on the cell surface, thereby transmitting signals to dampen immune cell activation [15], increased levels of sPD-L1 have been implicated in the perturbed anti-tumor immunity observed in cancer patients [11] and in the immune paralysis suffered by sepsis patients [19]. This evidence concerns the gene PDCD1 and cancer.